کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3383100 | 1220438 | 2012 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Nuevas dianas terapéuticas en el lupus sistémico (parte 2/2)
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
ایمونولوژی، آلرژی و روماتولوژی
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
Glucocorticoids, aspirin, conventional antimalarials and immunosuppressants are the mainstay of treatment of Systemic Lupus Erythematosus (SLE). Until recently, the first three were the only agents approved for treatment. A better understanding of the pathophysiology of the immune system has identified new therapeutic targets. In fact, belimumab, a human monoclonal antibody to BLyS inhibitor has become, in recent months, the first drug approved for the treatment of SLE since 1957, underscoring difficulties of all kinds, including economic and organizational ones inherent to clinical trials on this disease. Many other molecules are in various stages of development and soon will have concrete results. In this review, we examined the mechanism of action and most relevant clinical data for these molecules.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: ReumatologÃa ClÃnica - Volume 8, Issue 5, SeptemberâOctober 2012, Pages 263-269
Journal: ReumatologÃa ClÃnica - Volume 8, Issue 5, SeptemberâOctober 2012, Pages 263-269
نویسندگان
Walter A. Sifuentes Giraldo, MarÃa J. GarcÃa Villanueva, Alina L. Boteanu, Ana Lois Iglesias, Antonio C. Zea Mendoza,